Sarepta Therapeutics (STU:AB3A) Float Percentage Of Total Shares Outstanding: 83.42% (As of Jul. 13, 2026)


STU:AB3A Sarepta Therapeutics Inc STU:AB3A
54 GF Score
Price €16.54
GF Value €115.29
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Float Percentage Of Total Shares Outstanding?

Sarepta Therapeutics STU:AB3A -7.49% 54 Float Percentage Of Total Shares Outstanding is 83.42% as of Jul. 13, 2026. GuruFocus rates STU:AB3A with a GF Score™ of 54/100 and a GF Value™ of €115.29 (Possible Value Trap). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sarepta Therapeutics's float shares is 88.07 Mil. Sarepta Therapeutics's total shares outstanding is 105.58 Mil. Sarepta Therapeutics's float percentage of total shares outstanding is 83.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sarepta Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sarepta Therapeutics's Institutional Ownership is 54.51%.

STU:AB3A
54GF Score
Sarepta Therapeutics Inc STU:AB3A
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Sarepta Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=88.07/105.58
=83.42%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 83.42% mean?
Sarepta Therapeutics (STU:AB3A) has a Float Percentage Of Total Shares Outstanding of 83.42% as of Jul. 13, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Sarepta Therapeutics' current Float Percentage Of Total Shares Outstanding is 83.42%. Overall, Sarepta Therapeutics has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Float Percentage Of Total Shares Outstanding compare to ZYME and BCAX?
Sarepta Therapeutics' Float Percentage Of Total Shares Outstanding of 83.42% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Float Percentage Of Total Shares Outstanding is 83.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (STU:AB3A) is currently considered Possible Value Trap. The stock's GF Value™ is €115.29, compared to a current price of €16.54 — trading 85.7% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 83.42%. Sarepta Therapeutics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Sarepta Therapeutics (STU:AB3A), the current Float Percentage Of Total Shares Outstanding is 83.42% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (STU:AB3A) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of €16.54 is trading 85.7% below its estimated GF Value™ of €115.29. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for STU:AB3A:

  • Float Percentage Of Total Shares Outstanding: 83.42%
  • GF Value™: €115.29 vs. price of €16.54 (85.7% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the STU:AB3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
54GF Score

Get the complete analysis for STU:AB3A

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.54
Price
€115.29
GF Value